Lignaron

Lenalidomide, the active ingredient in Lignaron, is an immunomodulatory agent presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, specifically multiple myeloma and myelodysplastic syndromes, in adult patients who have disease progression after prior therapy.

GNH USA supplies Lignaron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution across multiple regions.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma cells or dysplastic marrow.

- Multiple Myeloma: improves progression‑free survival and overall response in adult patients. - Myelodysplastic Syndromes (del(5q)): reduces transfusion dependence and corrects cytopenias. - Mantle Cell Lymphoma (in combination): enhances response rates when added to rituximab‑based regimens.

Adverse reactions have been reported across clinical use.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools occurring intermittently. - Rash: skin redness or irritation.

Serious or Rare Side Effects: - Thromboembolic events: blood clots in veins or arteries. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before initiating therapy, several safety considerations should be observed.

- Pregnancy avoidance: contraindicated in pregnancy (Category X); ensure effective contraception. - Teratogenic risk: strict birth‑control measures required for both patient and male partners. - Blood monitoring: regular complete blood counts to detect cytopenias early. - Infection risk: monitor for signs of infection and manage promptly. - Thrombosis warning: assess risk factors for clot formation and consider prophylaxis when appropriate. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lenalidomide may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase lenalidomide exposure and toxicity. - Anticoagulants: additive risk of thromboembolic events. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce lenalidomide plasma levels, decreasing efficacy. - H2 antagonists or antacids: may affect gastrointestinal absorption. - Other immunomodulatory agents: monitor for overlapping immunosuppressive effects.